Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Curr Oncol Rep. 2012 Apr;14(2):158-65. doi: 10.1007/s11912-012-0216-1.
Organ preservation regimens that combine chemotherapy and radiotherapy (chemoradiotherapy) are increasingly used as the primary treatment of laryngeal and pharyngeal cancers. Meta-analytic data show a survival benefit with combined modality therapy, but the functional sequelae can be significant. Dysphagia is recognized as a common and often devastating late effect of chemoradiotherapy. This review examines functional outcomes after chemoradiotherapy for laryngeal and pharyngeal cancers, with a particular emphasis on dysphagia. Topics examined include the burden of dysphagia after chemoradiation, pathophysiology of dysphagia, baseline functioning, recommendations to improve long-term function, and voice outcomes.
保器官治疗方案，即联合化疗和放疗（放化疗），在喉癌和口咽癌的治疗中已越来越多地被作为首选方案。荟萃分析数据显示联合治疗具有生存获益，但功能后遗症可能较为显著。吞咽困难是放化疗后的常见且常具破坏性的晚期并发症。本综述评估了喉癌和口咽癌患者接受放化疗后的功能预后，重点关注吞咽困难。综述内容包括放化疗后吞咽困难的负担、吞咽困难的病理生理学、基线功能、改善长期功能的建议以及嗓音结果。
